Next Article in Journal
Genetic Characterization of Small Ruminant Lentiviruses (SRLVs) Circulating in Naturally Infected Sheep in Central Italy
Previous Article in Journal
Inactivation Rates for Airborne Human Coronavirus by Low Doses of 222 nm Far-UVC Radiation
 
 
Communication

Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor

1
Selecta Biotech SE, Istrijska 6094/20, 841 07 Bratislava, Slovakia
2
Biomedical Research Center, Department of Nanobiology, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia
3
Centre of Biosciences, Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Dubravska Cesta 9, 840 05 Bratislava, Slovakia
4
Department of Oncohematology, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Caijun Sun
Viruses 2022, 14(4), 685; https://doi.org/10.3390/v14040685
Received: 1 March 2022 / Revised: 15 March 2022 / Accepted: 23 March 2022 / Published: 25 March 2022
(This article belongs to the Section SARS-CoV-2 and COVID-19)
In only two years, the coronavirus disease 2019 (COVID-19) pandemic has had a devastating effect on public health all over the world and caused irreparable economic damage across all countries. Due to the limited therapeutic management of COVID-19 and the lack of tailor-made antiviral agents, finding new methods to combat this viral illness is now a priority. Herein, we report on a specific oligonucleotide-based RNA inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It displayed remarkable spontaneous cellular uptake, >94% efficiency in reducing RNA-dependent RNA polymerase (RdRp) RNA levels in transfected lung cell lines, and >98% efficiency in reducing SARS-CoV-2 RNA levels in samples from patients hospitalized with COVID-19 following a single application. View Full-Text
Keywords: SARS-CoV-2; COVID-19; RNA levels; oligonucleotide-based RNA inhibitor; RdRp SARS-CoV-2; COVID-19; RNA levels; oligonucleotide-based RNA inhibitor; RdRp
Show Figures

Figure 1

MDPI and ACS Style

Nemethova, V.; Mazancova, P.; Selc, M.; Jakic, K.; Uhelska, L.; Nemethova, B.; Poturnayova, A.; Drgona, L.; Babelova, A.; Razga, F. Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor. Viruses 2022, 14, 685. https://doi.org/10.3390/v14040685

AMA Style

Nemethova V, Mazancova P, Selc M, Jakic K, Uhelska L, Nemethova B, Poturnayova A, Drgona L, Babelova A, Razga F. Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor. Viruses. 2022; 14(4):685. https://doi.org/10.3390/v14040685

Chicago/Turabian Style

Nemethova, Veronika, Petra Mazancova, Michal Selc, Kristina Jakic, Lucia Uhelska, Boglarka Nemethova, Alexandra Poturnayova, Lubos Drgona, Andrea Babelova, and Filip Razga. 2022. "Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor" Viruses 14, no. 4: 685. https://doi.org/10.3390/v14040685

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop